A similar effect was observed in mice treated with a virus expressing IFNβ to treat plasmacytoma; ruxolitinib was able to rescue mice from lethal IFNβ toxicity without affecting anti-tumor immunity (Peng et al., 2017). Here, IFNB1 is linked to plasmacytoma.